# Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin

Study · id `cardio:ct-nct03076112` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03076112](<https://clinicaltrials.gov/study/NCT03076112>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03076112

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

## Technical summary

Registry record NCT03076112. Randomized; no masking; primary purpose treatment. Start 2017-04-25 (actual); primary completion 2022-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 170 participants (enrolled count; ClinicalTrials.gov record NCT03076112, source copy `cardio:ctgov-nct03076112-2022-10-04`, retrieved 2026-10-26)
- Started: 2017-04-25 (actual) (ClinicalTrials.gov record NCT03076112, source copy `cardio:ctgov-nct03076112-2022-10-04`, retrieved 2026-10-26)
- Primary completion: 2022-06-30 (actual) (ClinicalTrials.gov record NCT03076112, source copy `cardio:ctgov-nct03076112-2022-10-04`, retrieved 2026-10-26)
- Completion: 2022-08-31 (actual) (ClinicalTrials.gov record NCT03076112, source copy `cardio:ctgov-nct03076112-2022-10-04`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03076112, source copy `cardio:ctgov-nct03076112-2022-10-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03076112-2022-10-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ipragliflozin
- Intervention (Drug): Sitagliptin
- Lead sponsor: Seoul National University Bundang Hospital
- Lead sponsor class: OTHER
- Collaborator: Astellas Pharma Korea, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Seoul National University Bundang Hospital (`cardio:org-seoul-national-university-bundang-hospital`)
- Registry lists this organization as a collaborator: Astellas Pharma Korea, Inc. (`cardio:org-astellas-pharma-korea-inc`)

## Provenance

Content hash: 774040a346b7abbc011cceae53baa64d20489cfafcc542bab15c791f9d791469
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
